表紙
市場調査レポート

Tasigna(慢性骨髄性白血病):予測と市場分析

Tasigna (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 270718
出版日 ページ情報 英文 54 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
Tasigna(慢性骨髄性白血病):予測と市場分析 Tasigna (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022
出版日: 2013年05月15日 ページ情報: 英文 54 Pages
概要

当レポートでは、Tasigna(nilotinib)について調査分析し、慢性骨髄性白血病(CML)の概要と治療ガイドライン、競合情勢、製品情報、主要国の売上予測、売上情報などを提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 病因・病態生理
    • 病因
    • 病態生理
    • 臨床病期
    • 予後
    • 生活の質(QOL)
  • 症状

第4章 疾病管理

  • 世界の動向
    • 治療概要
    • 診断検査
    • 遺伝子検査
    • 患者の治療効果をモニタリング
    • 将来の方向性

第5章 競合評価

  • 概要
  • 競合企業の戦略的評価

第6章 製品プロファイル:Tasigna(nilotinib)

  • 概要
  • 効能
  • 安全性
  • SWOT分析
  • 予測

第7章 付録

図表

目次
Product Code: GDHC1138DFR

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, "Tasigna (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022". Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients' survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.

Novartis' Tasigna (nilotinib) is a second-generation BCR-ABL TKI. It was first approved in the US and 5EU in 2007 and in Japan in 2009 as a second-line therapy for patients with CP or AP CML that was intolerant or resistant to Gleevec. Shortly thereafter, in 2010, Tasigna gained regulatory approval for the first-line treatment of CP-CML patients in the US and the EU. In Japan, Tasigna received this brand extension in 2011. It is approved and reimbursed for both indications in all the 7MM. Tasigna has orphan drug designation from both the FDA and the EMA. Tasigna is administered twice daily at a dose of 300mg for newly diagnosed CP CML or 400mg when used as a second-line therapy, and must be taken on an empty stomach.

Scope

  • Overview of CML, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Tasigna including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Tasigna for the top seven countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for CML
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Tasigna performance
  • Obtain sales forecast for Tasigna from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Clinical Staging
    • 3.1.4. Prognosis
    • 3.1.5. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Global Trends
    • 4.1.1. Treatment Overview
    • 4.1.2. Diagnostic Tests
    • 4.1.3. Genetic Testing
    • 4.1.4. Monitoring Patient Response to Treatment
    • 4.1.5. Future Directions: Discontinuation Therapy

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Product Profile - Tasigna (nilotinib)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed CML patients
    • 7.4.2. Drug-treated Patients on X Line of Therapy
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Compliance Assumptions for Oral TKIs
    • 7.4.5. Individual Drug Assumptions
    • 7.4.6. Generic Erosion
    • 7.4.7. Pricing of New Market Entrants
  • 7.5. Physicians and Specialists Included in this Study
  • 7.6. Survey of High Prescribing Physicians
  • 7.7. About the Authors
    • 7.7.1. Authors
    • 7.7.2. Epidemiologists
    • 7.7.3. Global Director of Epidemiology and Clinical Trials Analysis
    • 7.7.4. Global Head of Healthcare
  • 7.8. About GlobalData
  • 7.9. Contact Us
  • 7.10. Disclaimer

List of Tables

  • Table 1: The Staging of CML as Defined by Commonly Used Staging Systems
  • Table 2: Prognostic Scoring Systems for CML
  • Table 3: Common Symptoms of CML by Disease Phase
  • Table 4: Most Commonly Followed Treatment Guidelines for CML
  • Table 5: Most Prescribed First-Line Therapies for CP, AP and BP CML in the Global Markets, 2013
  • Table 6: Suggested Treatments for CML Patients with Selected BCR-ABL Kinase Domain Mutations
  • Table 7: CML Response Types, Criteria, and Corresponding Tests
  • Table 8: Leading Treatments for Chronic Myeloid Leukemia, 2013
  • Table 9: Product Profile - Tasigna
  • Table 10: Molecular and Cytogenetic Responses of Tasigna Compared with Gleevec in Newly Diagnosed Ph+ CML in CP
  • Table 11: Tasigna SWOT Analysis, 2013
  • Table 12: Global Sales Forecasts ($m) for Tasigna in CML, 2012-2022
  • Table 13: Physicians Surveyed, by Country

List of Figures

  • Figure 1: Translocation of Chromosomes 9 and 22
  • Figure 2: Comparison of Normal and Leukemia Blood Cells
Back to Top